In the past, screening for DPD deficiency was considered unrealistic in the terms of cost, but available analyses suggest that DPYD genotype–guided dosing might significantly improve 5-FU therapy safety and cost [16,17]. The gene discussed is DPYD; the disease is hyperinsulinemic hypoglycemia, familial, 4.